Losartan

  • PDF / 296,254 Bytes
  • 18 Pages / 504.57 x 720 pts Page_size
  • 7 Downloads / 185 Views

DOWNLOAD

REPORT


Drugs 2005; 65 (18): 2657-2674 0012-6667/05/0018-2657/$39.95/0 © 2005 Adis Data Information BV. All rights reserved.

Losartan A Review of its Use in Stroke Risk Reduction in Patients with Hypertension and Left Ventricular Hypertrophy Marit D. Moen and Antona J. Wagstaff Adis International Limited, Auckland, New Zealand Various sections of the manuscript reviewed by: P.R. Conlin, Endocrinology, Diabetes and Hypertension Division, Brigham and Women’s Hospital, Boston, Massachusetts, USA; J.M. Flack, Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA; J. Kizer, Division of Cardiology, Weill Medical College of Cornell University, New York, New York, USA; S.E. Kjeldsen, Department of Cardiology, Ullevaal University Hospital, Oslo, Norway; F.H. Messerli, Division of Cardiology, St Luke’s-Roosevelt Hospital, New York, New York, USA. Data Selection Sources: Medical literature published in any language since 1980 on losartan, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: MEDLINE search terms were ‘losartan’ or ‘DUP-753’ or ‘MK-954’ and (‘hypertension’ or ‘hypertensive’) and (‘hypertrophy, left ventricular’ or ‘left ventricular hypertrophy’) and ‘stroke’. EMBASE search terms were ‘losartan’ or ‘DUP-753’ or ‘MK-954’ and (‘hypertension’ or ‘hypertensive’) and (‘heart left ventricle hypertrophy’ or ‘left ventricular hypertrophy’) and ‘stroke’. AdisBase search terms were ‘losartan’ or ‘DUP-753’ or ‘MK-954’ and (‘hypertension’ or ‘hypertensive’) and ‘left-ventricular-hypertrophy’ and ‘stroke’. Searches were last updated 21 November 2005. Selection: Studies in patients with hypertension and left ventricular hypertrophy who received losartan. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included. Index terms: Losartan, hypertension, left ventricular hypertrophy, stroke, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.

Contents Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2658 1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2659 2. Pharmacodynamic Profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2660 2.1 General Profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2660 2.2 Versus Atenolol .